Boomerang Medical, Inc., a women-led bioelectronic medicine company, today announced a $20 million Series B…
Arboretum_JDSeptember 4, 2025
Boomerang Medical Awarded “Promising Up-and-Comer in the Fight Against Ulcerative Colitis and Crohn’s Disease” by the Crohn’s & Colitis Foundation
Boomerang Medical, a women-led bioelectronic medicine company, received the Corporate Circle Award for "Promising Up-and-Comer…
Arboretum_JDFebruary 1, 2024
NewYork-Presbyterian Enrolls First Patient in National Study of Sacral Nerve Stimulation Device for Inflammatory Bowel Disease
For Marco B. Zoccali, MD, FACS, a colorectal surgeon at NewYork-Presbyterian/Columbia, sacral nerve stimulation (SNS) has…
Arboretum_JDMay 3, 2023
Boomerang Medical Announces First Patients Enrolled in Multi-Center Clinical Trial
Boomerang Medical, a women-led bioelectronic medicine company, has announced the enrollment of the first patients…
Arboretum_JDApril 17, 2023
Bioelectronic Medicine Company Boomerang Medical Earns FDA Breakthrough Device Designation
Boomerang Medical, a women-led bioelectronic medicine company, has been granted Breakthrough Device Designation from the…
Arboretum_JDMarch 1, 2023
Bioelectronic Medicine Company Boomerang Medical Raises $15M in Series A Financing
Returning investor Arboretum Ventures, joined by Hatteras Venture Partners, to fuel Boomerang Medical’s accelerated clinical…
Arboretum_JDNovember 1, 2022
